Stockscreener 앱 받기
13.01
11.29%
1.32
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics stock hits 52-week high at 12.65 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics stock hits 52-week high at 12.65 USD - Investing.com India
TNGX Analyst Rating Update: Piper Sandler Raises Price Target | TNGX Stock News - GuruFocus
Tango Therapeutics (NASDAQ:TNGX) Sets New 52-Week HighHere's Why - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq Futures Research-Driven Model - Kalkine Media
TNGX: Leadership shift supports late-stage trials and robust MTAP-deleted cancer pipeline progress - TradingView — Track All Markets
Tango Therapeutics (NASDAQ:TNGX) Trading 8.3% HigherShould You Buy? - MarketBeat
TNGX: Smooth leadership transition supports late-stage trials in MTAP-deleted cancers and robust 2026 milestones - TradingView — Track All Markets
Sentiment Review: Will Tango Therapeutics Inc stock recover after earningsEntry Point & Intraday High Probability Alerts - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.4%What's Next? - MarketBeat
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data - Investing.com Canada
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data By Investing.com - Investing.com India
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 29% - 富途牛牛
Does Tango Therapeutics’ (TNGX) CEO Transition Clarify or Complicate Its Precision Oncology Roadmap? - Yahoo Finance
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - Sahm
Can Tango Therapeutics Inc. stock sustain market leadershipJuly 2025 Macro Moves & Weekly Return Optimization Plans - Улправда
How Tango Therapeutics Inc. stock reacts to oil prices2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Tango Therapeutics Appoints Dr. Malte Peters as CEO - citybiz
Can Tango Therapeutics Inc. stock resist market sell offsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
Will Tango Therapeutics Inc. stock deliver long term returnsTrade Exit Summary & Daily Price Action Insights - Улправда
Tango Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 8, 2026 - marketscreener.com
Tango Therapeutics' CEO Retires, Successor Appointed; Shares Fall - MarketScreener
Is Tango Therapeutics Inc. stock a defensive play in 2025Dip Buying & Short-Term High Return Ideas - Улправда
Tango Therapeutics announces CEO transition: Barbara Weber to retire, Malte Peters appointed successor - marketscreener.com
Tango Therapeutics appoints Malte Peters as new CEO By Investing.com - Investing.com Australia
Tango Therapeutics appoints new CEO amid leadership transition - TipRanks
Tango Therapeutics appoints Malte Peters as new CEO - Investing.com
Tango Therapeutics Announces Leadership Transition: Barbara Weber, M.D. Becomes Executive Chair as Malte Peters, M.D. Assumes Role of President and CEO - Quiver Quantitative
Tango Therapeutics stock hits 52-week high at $11.21 By Investing.com - Investing.com Nigeria
Tango Therapeutics (NASDAQ:TNGX) Sets New 12-Month HighHere's What Happened - MarketBeat
Tango Therapeutics stock hits 52-week high at $11.21 - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.4%Here's What Happened - MarketBeat
Tango Therapeutics appoints Sung Lee to board of directors By Investing.com - Investing.com Nigeria
Tango Therapeutics adds independent director to strengthen governance - MSN
Tango Therapeutics Adds Independent Director to Strengthen Governance - TipRanks
Tango Therapeutics appoints Sung Lee to board of directors - Investing.com
Tango Therapeutics Appoints Sung Lee to Board of Directors - The Manila Times
Hindware Home Innovation Limited Reaches Critical Trendline SupportStraddle and Strangle Trades & Low Risk Investment Plans - earlytimes.in
Tango Therapeutics (NASDAQ:TNGX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Tango Therapeutics Advances TNG462 Study for MTAP-deleted Tumors - MSN
Patterns Watch: How Tango Therapeutics Inc stock reacts to oil pricesDip Buying & Safe Entry Point Identification - moha.gov.vn
Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why - MSN
3 Stocks With Strong Upside Potential for 2026 Gains - Tokenist
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026 - Investing.com
Certain Common Stock of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Pre-Funded Warrants of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - WV News
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Tango Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Sentiment & Fast Entry High Yield Tips - Улправда
Will Tango Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Trends & AI Driven Stock Reports - Улправда
Why Tango Therapeutics Inc. stock remains a top recommendationMarket Trend Report & Technical Pattern Based Signals - DonanımHaber
Will Tango Therapeutics Inc. stock deliver strong dividend growthProduct Launch & Real-Time Volume Analysis - DonanımHaber
4.73%
0.92%
자본화:
|
볼륨(24시간):